Get started
Author

Javier Aranda

Observed names: Aranda Pérez, Javier, Javier ARANDA, Javier Aranda Pérez, Javier Aranda-Pérez
ORCID: 0000-0002-9000-6670
Observed ORCID: 0000-0002-9000-6670
OpenAlex ID: A5036701622
Gemcitabine and docetaxel for high‐risk non‐muscle‐invasive bladder cancer: EuroGemDoce group results
2025 · Pietro Scilipoti, Mattia Longoni, et al. · British Journal of Urology · 26
PDF
Long-term Oncological Outcomes for Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment
2025 · Pietro Scilipoti, Mattia Longoni, et al. · European Urology Focus · 22
PDF
Indications, Complications and Side Effects of Ureteral Stents
2022 · Daniel Pérez-Fentes, Javier Aranda-Pérez, et al. · Springer eBooks · 22
PDF
Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer
2025 · Pietro Scilipoti, Mattia Longoni, et al. · British Journal of Urology · 21
Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma
2023 · Federico SORIA, Julia E. DELACRUZ, et al. · Minerva Urology and Nephrology · 15
Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study
2022 · Federico Soria, Salvador David Aznar-Cervantes, et al. · Polymers · 15
PDF
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high‐risk non‐muscle‐invasive bladder cancer
2026 · Pietro Scilipoti, Paolo Zaurito, et al. · British Journal of Urology · 5
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study
2026 · Pietro Scilipoti, Paolo Zaurito, et al. · World Journal of Urology · 2
Defining statistical cure in patients with T1 high‐grade non‐muscle‐invasive bladder carcinoma treated with BCG immunotherapy
2025 · José Daniel Subiela, Irene de la Parra, et al. · British Journal of Urology · 2
Ip02-12 Risk Stratification of Ta High-grade Non–muscle Invasive Bladder Cancer: Insights From a Multicenter Cohort Study
2026 · Paolo Zaurito, Pietro Scilipoti, et al. · The Journal of Urology · 1
Surrogacy of intermediate clinical endpoints for overall survival in BCG-naïve high-risk non-muscle-invasive bladder cancer
2026 · Pietro Scilipoti, Aleksander Ślusarczyk, et al. · World Journal of Urology
Ip20-02 Bcg-rechallenge After Treatment Failure: Long-term Outcomes From a Multi-institutional Cohort
2026 · Paolo Zaurito, Pietro Scilipoti, et al. · The Journal of Urology
Ip20-03 Real-world Outcomes of Bladder-sparing Strategies for Bcg-unresponsive Non-muscle-invasive Bladder Cancer: a Multicenter Study
2026 · Pietro Scilipoti, Aleksander Ślusarczyk, et al. · The Journal of Urology
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette–Guérin
2026 · Pietro Scilipoti, Paolo Zaurito, et al. · Urologic Oncology Seminars and Original Investigations
Risk stratification of Ta high-grade non–muscle-invasive bladder cancer: Insights from a multicenter cohort study
2026 · Paolo Zaurito, Pietro Scilipoti, et al. · Urologic Oncology Seminars and Original Investigations
Ip02-05 Comparative Analysis of Bacillus Calmette-guérin Therapy Versus Immediate Radical Cystectomy in High-risk and Very High-risk Non-muscle Invasive Bladder Cancer: a European Multicenter Study
2025 · Pietro Scilipoti, Mattia Longoni, et al. · The Journal of Urology
PDF
Ip02-20 Intravesical Gemcitabine and Docetaxel for High-risk Non-muscle Invasive Bladder Cancer Previously Treated With Bcg: Results From the Eurogemdoce Group
2025 · Pietro Scilipoti, Mattia Longoni, et al. · The Journal of Urology
Priapism. First symptom in prostate cancer
2022 · José Luis Rodríguez, Javier Aranda Pérez, et al.
Works count: 19
Citation count: 131
H-index: 6
I10-index: 6
Year
Topic
Type